Zevra Therapeutics (ZVRA) Free Cash Flow (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Free Cash Flow data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Free Cash Flow rose 173.39% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 119.4% YoY) and the FY2025 annual result came in at -$2.4 million, up 96.51% from the prior year.
• Free Cash Flow climbed to $6.1 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $6.9 million in Q1 2022 to a low of -$19.1 million in Q2 2024.
• A 5-year average of -$7.0 million and a median of -$6.6 million in 2022 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 367.68% in 2022, down 364.39% in 2022.
• Tracing ZVRA's Free Cash Flow over 5 years: stood at -$4.0 million in 2022, then tumbled by 304.03% to -$16.2 million in 2023, then declined by 0.12% to -$16.2 million in 2024, then jumped by 134.14% to $5.5 million in 2025, then grew by 10.1% to $6.1 million in 2026.
• The last three Free Cash Flow figures came in at $6.1 million (Q1 2026), $5.5 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.